ATS-9R: Precision Adipocyte-Targeting Non-Viral Gene Delivery Oligopeptide

Executive Summary: ATS-9R (Adipocyte-targeting sequence-9-arginine) is a fusion oligopeptide designed for non-viral, prohibitin-mediated gene delivery specifically to white adipose tissue (WAT) and adipose tissue macrophages (ATMs) (APExBIO). The 18-mer peptide contains a nona-arginine (9R) motif that enhances nucleic acid condensation and cellular penetration (Huang et al., 2022). ATS-9R forms nanoparticles (150–354 nm, zeta potential 7–20 mV) with nucleic acids at 3:1 or 6:1 peptide:nucleic acid weight ratios. In vivo, these complexes selectively accumulate in visceral and subcutaneous adipose tissue, sparing the liver except as a clearance organ. Gene silencing with ATS-9R achieves 30–70% mRNA knockdown of targets like FAM83A and CCL2 with minimal cytotoxicity and no significant hepatic or renal toxicity.

Biological Rationale

Obesity is characterized by excessive white adipose tissue, which is central to energy storage and metabolic regulation (Huang et al., 2022). Dysfunctional WAT contributes to the pathogenesis of obesity-associated diseases such as insulin resistance, type 2 diabetes, and gestational diabetes mellitus (GDM). Targeting adipocytes and adipose tissue macrophages enables precise intervention in metabolic processes and inflammation (see contrast: this article expands on in vivo targeting selectivity). Conventional viral vectors pose safety, immunogenicity, and manufacturing challenges. Non-viral, peptide-based delivery offers safer, tunable alternatives for gene silencing in adipocytes. Prohibitin, a surface protein highly expressed on mature adipocytes and ATMs, serves as a selective entry point for peptide-mediated delivery platforms such as ATS-9R.

Mechanism of Action of ATS-9R (Adipocyte-targeting sequence-9-arginine)

ATS-9R is an 18-residue peptide (Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Cys, CAS No. 2431960-42-6) featuring a central nona-arginine sequence. The peptide binds to prohibitin on the surface of white adipocytes and ATMs, enabling targeted endocytosis (see contrast: this article details competition with alternative endocytosis pathways). The 9R motif condenses nucleic acids (shRNA, sgRNA/Cas9, siRNA, plasmids) and facilitates their penetration across plasma and endosomal membranes. Once internalized, ATS-9R releases its nucleic acid cargo intracellularly, enabling potent gene silencing. This has been demonstrated for targets such as TACE, CCL2, FAM83A, and Fabp4. The peptide–nucleic acid complexes are formulated at specific weight ratios (3:1 or 6:1), verified by agarose gel retardation assays. Nanoparticle sizing (150–354 nm) and zeta potential (7–20 mV) optimize cellular uptake and minimize aggregation.

Evidence & Benchmarks

• ATS-9R:sgRNA/Cas9 complexes targeting FAM83A delivered in vivo to mice achieved 30–70% mRNA knockdown in white adipose tissue within 7 days (Huang et al. 2022, DOI).
• Formulated nanoparticles (3:1 or 6:1 peptide:nucleic acid w/w) exhibit stable diameters (150–354 nm) and positive zeta potentials (7–20 mV), maximizing uptake and dispersion (APExBIO).
• Targeted delivery results in high accumulation in visceral (epiWAT) and subcutaneous (subWAT) adipose tissues, but not in liver or other non-target organs (Huang et al. 2022, DOI).
• In vitro, 10–25 μg/ml ATS-9R with 5 μM–2 μg nucleic acid yields >80% cell viability and robust gene silencing in 3T3-L1 adipocytes (internal summary).
• In animal models, repeated intraperitoneal injections (0.2–0.35 mg/kg ATS-9R, 0.35–0.7 mg/kg nucleic acid) are well tolerated and clear predominantly via the liver in 12–24 hours (APExBIO).
• Knockdown of FAM83A in adipocytes reduces adipose tissue mass, lipid accumulation, and improves mitochondrial structure (Huang et al. 2022, DOI).
• Gel retardation assays confirm >95% condensation efficiency at ≥3:1 peptide:nucleic acid ratio (APExBIO).

Applications, Limits & Misconceptions

ATS-9R enables targeted gene silencing for obesity research, insulin resistance, GDM, and type 2 diabetes models. Silencing of genes such as FAM83A and CCL2 modulates adipocyte differentiation, lipid storage, and inflammation (Huang et al., 2022). Applications include:

• Attenuation of obesity-associated inflammation via selective knockdown in ATMs.
• Amelioration of insulin resistance by targeting genes regulating adipogenesis and cytokine production.
• Research models for gestational diabetes and obesity-induced metabolic syndrome.
• Low-toxicity, non-viral gene delivery for in vivo and in vitro adipocyte manipulation.

Compared to prior reviews on ATS-9R strategy, this article provides updated, quantitative benchmarks and clarifies nanoparticle formulation conditions.

Common Pitfalls or Misconceptions

• ATS-9R does not efficiently target non-adipocyte tissues (e.g., liver, muscle, brain) due to its dependence on prohibitin expression.
• It is not suitable for delivery of large protein cargoes; nucleic acids (shRNA, sgRNA/Cas9, siRNA, plasmid DNA) are optimal substrates.
• Complexes must be freshly prepared and protected from elevated temperatures; storage at -20°C is required to maintain targeting efficiency (APExBIO).
• Overloading nucleic acids (>6:1 peptide:nucleic acid ratio) may cause aggregation and reduce delivery efficiency.
• Use in non-murine models requires validation of prohibitin surface expression and pharmacokinetics.

Workflow Integration & Parameters

ATS-9R is supplied as a peptide, soluble in DMSO, and packaged as product C8721 by APExBIO (product page). For in vitro transfection, complexes are formed by mixing 10–25 μg/ml peptide with 5 μM–2 μg nucleic acid per well in serum-free medium, incubated at room temperature for 15–30 minutes. In vivo, intraperitoneal injections are performed at 0.2–0.35 mg/kg peptide and 0.35–0.7 mg/kg nucleic acid, administered twice weekly or as four consecutive doses. Nanoparticle formation should be confirmed by agarose gel retardation and dynamic light scattering (DLS). Cell viability and knockdown efficiency should be validated by qPCR and flow cytometry. Clearance occurs via the liver within 12–24 hours; sampling schedules should reflect this pharmacokinetic profile. Researchers should prepare fresh complexes before each use and avoid repeated freeze-thaw cycles. For extended protocols and troubleshooting, see this technical guide (this article offers new data on long-term in vivo clearance and tissue selectivity).

Conclusion & Outlook

ATS-9R (Adipocyte-targeting sequence-9-arginine) represents a validated, non-viral platform for precise nucleic acid delivery to white adipose tissue. Its prohibitin-mediated targeting and robust condensation of nucleic acids enable high-efficiency, low-toxicity gene silencing in adipocytes and ATMs. These features support applications in obesity-associated inflammation, insulin resistance, GDM, and type 2 diabetes research. Future investigations should evaluate cross-species applicability, optimize dosing for larger animal models, and explore combinatorial gene targeting strategies. For product details and ordering, visit the APExBIO ATS-9R product page.